Canaccord lowered the firm’s price target on Niagen Bioscience (NAGE) to $14 from $16 and keeps a Buy rating on the shares. The firm said they posted a Q3 beat as they continue to see strong demand for the flagship TruNiagen supplement businesses, leading to total company sales up +32.9% vs. our/Street estimate of +22.6%/+22.0%.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE: